medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 5

<< Back Next >>

Ann Hepatol 2016; 15 (5)

Effect of ezetimibe in HCV viral load after liver transplantation

Monrroy-Bravo H, Angulo J, Pino K, Labbé P, López-Lastra M, Soza A

Language: English
References: 12
Page: 803-805
PDF size: 110.04 Kb.


Text Extraction

Dear Editor:

Chronic hepatitis C virus (HCV) infection is the leading reason for liver transplantation in Western countries. Unfortunately, reinfection of the graft is universal after transplantation, occurring early at reperfusion.3 There is no accepted approach for preventing reinfection, but strategies aimed at blocking viral entry to the hepatocyte seem interesting in this clinical scenario. HCV circulates in human serum associated with various lipoproteins, including HDL, LDL and VLDL, forming lipo-viral particles (LVP), and among the various entry factors described, several are related to lipoprotein receptors, including LDL receptor7 and scavenger receptor class B type I (SCARB1, also known as SR-BI).


REFERENCES

  1. Rubin A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 805-12.

  2. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, Combs C, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-22.

  3. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, Lobeck H, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24: 1351-4.

  4. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999: 96: 12766-71.

  5. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 1992; 181: 293- 300.

  6. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-28.

  7. Owen DM, Huang H, Ye J, Gale M, Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394: 99-108.

  8. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-25.

  9. Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, et al. Identification of the Niemann- Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-5.

  10. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-7.

  11. Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, et al. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015; 64: 483-94.

  12. Pawlotsky JM. Viral entry inhibition: too late for hepatitis C, but promising for other viral infections. Gut 2015; 64: 362-4.




2020     |     www.medigraphic.com